Global Onychomycosis Drug Market, By Types (Proximal Subungual, Distal Subungual, Candidal, White Superficial and Total Dystrophic), Drugs (Griseofulvin, Ketoconazole, Ciclopirox, Terbinafine and Others), Treatment (Medication, Topical Therapy and Debridement), Route of Administration (Oral, Topical and Others), Distribution Channel (Direct, Online Pharmacy, Retailers and Others), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights of Onychomycosis Drug Market
Data Bridge Market Research analyses that the onychomycosis drug will exhibit a CAGR of around 5.94% for the forecast period of 2021-2028. Rising government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies, rising prevalence of onychomycosis and increased expenditure for research and development activities are the major factors attributable to the growth of onychomycosis drug market.
Also known as tinea unguium, onychomycosis is a fungal infection that develops in finger nails and toe nails. Onychomycosis can lead to disfigurement, discomfort, pain, and may cause serious issues. The main symptom of this disease is changes in the appearance of nails such as white or yellow nail discoloration.
Rising awareness about the treatment coupled with rising prevalence of onychomycosis is a major factor fostering the growth of onychomycosis drugmarket. Rising expenditure on the development of healthcare infrastructure, ever-rising geriatric population and rising personal disposable income is also fostering the growth of the market. Also, rising research and development activities by biotechnology and pharmaceutical companies for the development of novel drugs and therapies will create lucrative market growth opportunities for this market.
However, patent expiry of several companies will pose a major challenge to the onychomycosis drug market growth. High capital requirement for research and development proficiencies will further derail the market growth rate. Also, lack of awareness regarding onychomycosis in some middle income and low income countries will further challenge the market growth rate.
This onychomycosis drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on onychomycosis drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Onychomycosis Drug Market Scope and Market Size
The onychomycosis drug market is segmented on the basis of types, drugs, treatment, route of administration, distribution channel and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on types, the onychomycosis drug market is segmented into proximal subungual, distal subungual, candidal, white superficial and total dystrophic.
- On the basis of drugs, the onychomycosis drug market is segmented into griseofulvin, ketoconazole, ciclopirox, terbinafine and others.
- On the basis of treatment, the onychomycosis drug market is segmented into medication, topical treatment and debridement.
- On the basis of route of administration, the onychomycosis drug market is segmented into oral, topical and others.
- On the basis of distribution channel, the onychomycosis drug market is segmented into direct, online pharmacy, retailers and others.
- On the basis of end users, the onychomycosis drug market is segmented into hospitals, homecare, specialty clinics and others.
Global Onychomycosis Drug Market Country Level Analysis
Global onychomycosis drug market is analysed and market size insights and trends are provided by country, types, drugs, treatment, route of administration, distribution channel and end users as referenced above.
The countries covered in the onychomycosis drug market report are the U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the onychomycosis drug market owing to the prevalence of advanced healthcare infrastructure and rising prevalence of onychomycosis. Asia-Pacific is projected to score highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop healthcare infrastructure coupled with rising awareness about onychomycosis.
The country section of the onychomycosis drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The onychomycosis drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to onychomycosis drug market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the onychomycosis drug market in the growth period.
Competitive Landscape and Onychomycosis Drug Market Share Analysis
The onychomycosis drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to onychomycosis drug market.
The major players covered in the onychomycosis drug market report are Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Astrazeneca, Pfizer Inc., Sanofi, Johnson & Johnson Services, Inc., AbbVie Inc., Allergan, Merck & Co., Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Bausch Health Companies Inc., GALDERMA and Moberg Pharma AB among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.